Cheers to five years of dedication from our fantastic Volastra team in the fight against #cancer. As we look back on our team’s accomplishments and milestones, we’re proud of our growth and grateful for our collective commitment to advancing life-changing therapies for patients.

Heading to #ASCO24 next week? Join us as we provide an overview of our Phase I/II #clinicaltrial of VLS-1488, one of our clinical-stage #KIF18A inhibitors for patients with advanced #cancers. Details below and view our full abstract here: meetings.asco.org/abstracts-pres… ASCO

We’re on the ground at #ASCO24 in Chicago! Connect with us to learn more about our #clinicaltrial evaluating our internally discovered #KIF18A inhibitor, VLS-1488, in patients with advanced #cancers. View the abstract here: meetings.asco.org/abstracts-pres… ASCO

#DYK 60%-80% of all cancers are chromosomally unstable? Check out Ben Comer’s latest ‘Companies to Watch’ feature, where our CEO charles hugh-jones discusses exploiting chromosomal instability (CIN) in #cancer cells & our two clinical-stage #KIF18A inhibitors: ow.ly/uQHy50SrUAP

Earlier this week, the Volastra team came together for a fun-filled afternoon at Yankee Stadium. Taking a break from the office allowed us to relax and recharge, and to top it off, the Yankees won 9-1! ⚾️🌞 Here’s to continued teamwork, both on and off the field!

Our co-founder, Dr. Samuel Bakhoum’s pioneering work linking #chromosomal_instability (CIN) to #cancer progression forms the backbone of our research strategy which exploits CIN to develop transformative treatments for cancer patients. FierceBiotech: bit.ly/4g8NzgG

It’s #OvarianCancerAwarenessMonth & we’re highlighting the role of CIN in one of the most hard-to-treat cancers: HGSOC. At Volastra, we’re developing new therapies for ovarian cancer by leveraging KIF18A inhibition to exploit CIN: bit.ly/4eiswGB & bit.ly/4ebScVs

We’re proud sponsors of this year’s FASEB Consequences of Aneuploidy Conference! Christina Eng, our Vice President, Biology, is on-site this week—be sure to connect with her while you are there! #ANESRC

The U.S. FDA has granted Fast Track designation to VLS-1488, our internally discovered #KIF18A inhibitor for the treatment of #patients with HGSOC, further underscoring its potential to address the high unmet need in treating this devastating disease. bit.ly/3N79bgf

Over the past 5 years, Volastra has focused on targeting #chromosomal_instability—a key driver of #cancer—and our 2 #clinical stage #KIF18A inhibitors are just the beginning. Our, CEO charles hugh-jones, MD, reflects on our journey & latest progress: lnkd.in/eF_TBw8d

We're hiring! Volastra is looking for a Data Engineer/Sr. Data Engineer to build scalable data infrastructure that drives cutting-edge oncology research. If you're passionate about data + biotech, apply here: linkedin.com/jobs/view/4140… #BiotechCareers #Oncology #Hiring #Data

As #SGO2025 wraps up, we’re grateful for the connections & conversations with investigators leading ovarian cancer research. With expansion cohorts now open in our KIF18Ai #clinicaltrial, we’re excited for the progress ahead! #Oncology #ClinicalResearch #SGOMtg #AM25IMPACT

Excited to share that Volastra will present preliminary results from our first-in-human Phase I/II trial of VLS-1488 - a novel oral #KIF18A inhibitor - at #ASCO25 next month. This marks the first public release of KIF18A inhibitor clinical data: meetings.asco.org/2025-asco-annu…

Proud to sponsor the EMBO Aneuploidy & Chromosome Segregation Workshop—an inspiring few days of cutting-edge CIN science. Grateful to connect with leaders in the field, including our CSO Samuel Bakhoum, as we push forward new therapies for CIN-driven cancers. #EMBO2025

On #WorldOvarianCancerDay, we honor the patients, families & communities affected by this devastating disease. Their stories drive our mission at Volastra—to bring new treatment options to those who need them most. #WOCD2025

Volastra is thrilled to share encouraging initial data from the dose escalation portion of our Phase I/II trial of our novel #KIF18A inhibitor, VLS-1488, at #ASCO2025 in Chicago. More details here: volastratx.com/initial-data-f…

Early findings from a first-in-human trial of VLS-1488, an oral KIF18A inhibitor, show promising anti-tumor activity in heavily treated ovarian cancer. No dose-limiting toxicities were observed. Presented by Dr. Ecaterina Dumbrava at #ASCO25. #EndCancer

A proud moment at #ASCO25: data from the dose escalation portion of our Phase I/II study for our novel #KIF18A inhibitor, VLS-1488, earned a spot at the podium. This milestone reflects the momentum behind #KIF18A inhibition and the dedication of our team and partners.

Pleased to share that our CEO, David Southwell, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept 9. We’ll discuss our clinical-stage KIF18A inhibitors and mission to develop novel cancer therapeutics. #Oncology #Biotech #CIN